Tessa Therapeutics, a Temasek-backed clinical stage biotech company, has announced raising $126 million in a Series A funding round led by US-based healthcare and technology investor Polaris Partners.
Existing investors Temasek, EDBI, Heliconia Capital, and Heritas Capital also participated in the funding round that Tessa said will be used to finance the ongoing clinical development of its therapy programmes.
